Skip to content Skip to footer
Subscribe Now
Viewpoints_Mark Gurney
VIEWPOINTS

PharmaShots Interview: Tetra Therapeutics’ Mark Gurney Shares Insight on Topline Results of BPN14770 for Fragile X Syndrome

In an interview with PharmaShots, Mark Gurney, CEO at Tetra Therapeutics shared his views on the results of the P-II exploratory study of BPN14770 in adult patients with Fragile X Syndrome. Shots: The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG…
March 1, 2021

Read more

Viewpoints_Ying Huang
VIEWPOINTS

PharmaShots Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends' collaboration with Janssen. Shots: The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were recently presented at the 62nd ASH Meeting The…
February 25, 2021

Read more

Viewpoints_Dr. Sophia Randolph
VIEWPOINTS

PharmaShots Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology's collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots: Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination…
February 22, 2021

Read more

Viewpoints_Mathew L. Sherman
VIEWPOINTS

PharmaShots Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020 Shots: Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014 in tenosynovial giant cell tumor…
February 17, 2021

Read more

Viewpoints_Bradley Galer
VIEWPOINTS

PharmaShots Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease. Shots: Fintepla was approved by the EC in Dec'2020 as a new add-on therapy to…
February 16, 2021

Read more

Viewpoints_Nathalie Landry
VIEWPOINTS

PharmaShots Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

In an interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago shared her views on positive results of P-I clinical trial results for its plant-derived COVID-19 vaccine.  Shots: The results of the trial demonstrated that 100% of participants developed a promising antibody response after two doses of Medicago's COVID-19 adjuvanted vaccine candidate The vaccine…
February 15, 2021

Read more

Viewpoints_Andreas Harstrick
VIEWPOINTS

PharmaShots Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two…
February 10, 2021

Read more

Viewpoints_Duncan Short
VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Duncan Short Shares Insight on PROgress Study Demonstrating that Pre-Visit Survey Can Improve HIV Care

In a recent interview with PharmaShots, Duncan Short, Ph.D., Director of Global Implementation Science at ViiV Healthcare shared his views on the findings of a new study demonstrating how the inclusion of a brief survey focused on patient-reported outcomes (PROs) during doctor's appointments can improve HIV care. Shots: In the study, people living with HIV were provided…
February 8, 2021

Read more

Viewpoints_Edouard Gasser
VIEWPOINTS

PharmaShots Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight

In a recent interview with PharmaShots, Edouard Gasser, CEO of Tilak Healthcare shared his views on OdySight, which is the first medical game to monitor eyesight for patients with chronic eye diseases. Shots: OdySight is a free mobile game and medical-grade application used to remotely monitor patients suffering from chronic maculopathies such as AMD, macular edema, and diabetic retinopathy…
February 4, 2021

Read more

Load more